Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

Recruiting

Phase 2

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

Sponsor:

University of Chicago

Code:

NCT05068232

Conditions

Small-cell Lung Cancer

Extensive-stage Small-cell Lung Cancer

Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Ablative Radiation

Durvalumab

Etoposide

Carboplatin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by University of Chicago on 2025-01-27.